Colitis Ulcerative Clinical Trials

29 recruitingLast updated: June 18, 2026

There are 29 actively recruiting colitis ulcerative clinical trials across 45 countries. Studies span Phase 2, Phase 3, Not Applicable. Top locations include San Antonio, Texas, United States, New York, New York, United States, Berlin, Germany. Updated daily from ClinicalTrials.gov.


Colitis Ulcerative Trials at a Glance

29 actively recruiting trials for colitis ulcerative are listed on ClinicalTrialsFinder across 6 cities in 45 countries. The largest study group is Phase 2 with 8 trials, with the heaviest enrollment activity in San Antonio, New York, and Berlin. Lead sponsors running colitis ulcerative studies include Janssen Research & Development, LLC, Pfizer, and Merck Sharp & Dohme LLC.

Browse colitis ulcerative trials by phase

Treatments under study

About Colitis Ulcerative Clinical Trials

Looking for clinical trials for Colitis Ulcerative? There are currently 29 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Colitis Ulcerative trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Colitis Ulcerative clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 29 trials

Recruiting
Phase 2

A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

Ulcerative ColitisColitis Ulcerative
Merck Sharp & Dohme LLC100 enrolled9 locationsNCT07463183
Recruiting
Phase 2

Confirmatory Clinical Study in Active Ulcerative Colitis

Colitis Ulcerative
MRM Health NV204 enrolled10 locationsNCT07296315
Recruiting
Phase 2Phase 3

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

Colitis Ulcerative
Bristol-Myers Squibb120 enrolled90 locationsNCT05076175
Recruiting

A Study to Assess Real-world Outcomes for Long-Term Use of Guselkumab

Crohn DiseaseInflammatory Bowel DiseaseColitis Ulcerative
Janssen-Cilag A.G., Switzerland50 enrolled1 locationNCT07532213
Recruiting
Phase 3

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

Colitis UlcerativeArthritis, PsoriaticCrohns Disease+1 more
Janssen Research & Development, LLC196 enrolled47 locationsNCT06663332
Recruiting
Phase 2

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

ColitisInflammatory Bowel DiseasesUlcerative Colitis+1 more
Spyre Therapeutics, Inc.645 enrolled223 locationsNCT07012395
Recruiting

A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)

Crohn's DiseaseInflammatory Bowel DiseaseColitis Ulcerative
Janssen-Cilag Ltd.220 enrolled1 locationNCT07242248
Recruiting

A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany

Crohn's DiseaseInflammatory Bowel DiseaseColitis Ulcerative
Janssen-Cilag G.m.b.H500 enrolled1 locationNCT07102368
Recruiting

A Real-World Study of Guselkumab in Chinese Participants With Ulcerative Colitis

Colitis Ulcerative
Xian-Janssen Pharmaceutical Ltd.200 enrolled9 locationsNCT07302360
Recruiting
Phase 3

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

Colitis Ulcerative
Janssen Research & Development, LLC882 enrolled393 locationsNCT07196748
Recruiting
Phase 3

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

Colitis Ulcerative
Janssen Research & Development, LLC644 enrolled6 locationsNCT07577856
Recruiting
Phase 2

A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

Crohn DiseaseColitis Ulcerative
Eli Lilly and Company60 enrolled72 locationsNCT07483073
Recruiting
Phase 2

A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis

Colitis Ulcerative
Sanofi204 enrolled115 locationsNCT06867094
Recruiting

A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants

Arthritis, RheumatoidColitis Ulcerative
Eisai Korea Inc.2,040 enrolled65 locationsNCT06246123
Recruiting
Phase 3

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

Crohn DiseaseColitis Ulcerative
Merck Sharp & Dohme LLC1,380 enrolled37 locationsNCT06651281
Recruiting

A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis

Crohn DiseaseColitis Ulcerative
Janssen Scientific Affairs, LLC1,056 enrolled1 locationNCT04372108
Recruiting
Phase 2

A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis

Colitis Ulcerative
Pfizer24 enrolled9 locationsNCT07470879
Recruiting

An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis

Colitis Ulcerative
Pfizer300 enrolled22 locationsNCT06398626
Recruiting

Therapeutic Endpoint in Pediatric IBD Conditions

Inflammatory Bowel DiseasesCrohn DiseaseColitis Ulcerative
Children's National Research Institute60 enrolled1 locationNCT06065228
Recruiting

A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis

Colitis Ulcerative
Pfizer360 enrolled34 locationsNCT06294925